Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026)

Neurocrine Biosciences (NBIX) has reported Operating Leases for 8 consecutive years, with $461.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 5.76% year-over-year to $461.6 million; the trailing twelve-month figure through Jun 2026 stood at $461.6 million (down 5.76% YoY), and the FY2025 full-year result was $415.3 million, down 8.75% from the prior year.
• Operating Leases held at $461.6 million in Q2 2026 per NBIX's latest filing, from $463.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $493.1 million in Q1 2025 and bottomed at $93.5 million in Q4 2022.
• Historically, Operating Leases has averaged $285.8 million across 5 years, with a median of $287.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Leases retreated 11.21% in 2022, then surged 176.26% in 2023.
• Over 5 years, Operating Leases stood at $93.5 million in 2022, then surged by 176.26% to $258.3 million in 2023, then soared by 76.19% to $455.1 million in 2024, then fell by 8.75% to $415.3 million in 2025, then increased by 11.15% to $461.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $461.6 million, $463.5 million, and $415.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.